<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04678817</url>
  </required_header>
  <id_info>
    <org_study_id>137011</org_study_id>
    <nct_id>NCT04678817</nct_id>
  </id_info>
  <brief_title>Same Day Oral EC and Implant Initiation</brief_title>
  <official_title>A Prospective Observational Study of Preference for and Efficacy of Oral Levonorgestrel Emergency Contraception With Same Day Etonogestrel Contraceptive Implant Compared to Established Pregnancy Rates With Oral Levonorgestrel Emergency Contraception Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study for clients presenting for emergency contraception (EC). EC is used to&#xD;
      prevent pregnancy after unprotected intercourse. Clients presenting for EC may be offered&#xD;
      either the copper or hormonal IUD or oral EC. Current guidelines allow for same-day implant&#xD;
      initiation at the time of an EC encounter, as long as oral LNG EC is co-administered. This&#xD;
      study will look at pregnancy rates and clients willingness to receive same-day implant + oral&#xD;
      EC and same-day IUDs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recommended options for EC include oral EC (levonorgestrel (LNG), ulipristal acetate (UPA),&#xD;
      or combination oral contraceptive pills), or the copper intrauterine device (IUD). Recent&#xD;
      data will also allow women presenting for EC to be offered the LNG IUD. These recommendations&#xD;
      leave out the only other long-acting reversible contraceptive (LARC), the ENG implant.&#xD;
      Current guidelines allow for same-day ENG implant initiation at the time of an EC encounter,&#xD;
      as long as oral LNG EC is co-administered. We lack data on pregnancy risk for the EC-eligible&#xD;
      population desiring same-day ENG implant placement and oral EC.&#xD;
&#xD;
      Women presenting for EC often need ongoing contraception, but clinical practice is not&#xD;
      standardized in same-day counseling and initiation due to system, provider, and client-level&#xD;
      barriers. Interest in LARC use continues to increase as well as same-day contraception&#xD;
      initiation at the time of an EC encounter. Women presenting for EC may not have considered&#xD;
      LARC options before. Generating estimates and continuation rates for same-day initiation with&#xD;
      an EC encounter will improve contraceptive options for women seeking EC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate at one-month</measure>
    <time_frame>one month</time_frame>
    <description>To determine a point estimate for the one-month pregnancy rate following guideline supported same-day initiation of an etonogestrel (ENG) implant plus oral levonorgestrel (LNG) emergency contraception (EC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparing Proportions of EC clients desiring ENG implant with oral EC vs IUD</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the proportion of EC clients willing to initiate a same-day ENG implant with oral LNG EC compared to same-day initiation of intrauterine devices for EC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuation Rates</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>6- and 12-month continuation rates of the ENG implant with same-day initiation at an EC encounter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation Timing and Reasons</measure>
    <time_frame>12 months</time_frame>
    <description>Timing and reasons for ENG implant discontinuation in the 12 months following same-day initiation at an EC encounter.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Contraception</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will be recruited from participating Planned Parenthood of Utah clinics.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy women&#xD;
&#xD;
          -  Age 18-35 years&#xD;
&#xD;
          -  Fluent in English and/or Spanish&#xD;
&#xD;
          -  BMI &lt; 30 kg/m2&#xD;
&#xD;
          -  No known contraindication to either the ENG contraceptive implant or oral LNG EC using&#xD;
             the CDC Medical Eligibility Criteria for Contraceptive Use 2016&#xD;
&#xD;
          -  Negative urine pregnancy test&#xD;
&#xD;
          -  Willing to abstain from further UPI in the 7 days following insertion&#xD;
&#xD;
          -  Know the date of their last menstrual period&#xD;
&#xD;
          -  Regular menstrual cycle (24-35 days)&#xD;
&#xD;
          -  Be willing to comply with the study requirements&#xD;
&#xD;
          -  Desiring to avoid pregnancy for at least 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current pregnancy or breastfeeding&#xD;
&#xD;
          -  Previous use of oral EC in the current cycle&#xD;
&#xD;
          -  Report of UPI beyond 5 days in current cycle&#xD;
&#xD;
          -  Vaginal bleeding of unknown etiology&#xD;
&#xD;
          -  Allergy to LNG or ENG, IUD or implant in-place&#xD;
&#xD;
          -  History of permanent contraception through sterilization or hysterectomy&#xD;
&#xD;
          -  Monogamous partner with a vasectomy&#xD;
&#xD;
          -  Depo-provera injection within past 15 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Gawron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne Sexsmith</last_name>
    <phone>801-213-2522</phone>
    <email>corinne.sexsmith@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Gibson</last_name>
    <phone>801-213-2845</phone>
    <email>marie.gibson@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Planned Parenthood Association of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Sexsmith</last_name>
      <phone>801-213-2522</phone>
      <email>corinne.sexsmith@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marie Gibson</last_name>
      <phone>801-213-2845</phone>
      <email>marie.gibson@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lori Gawron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Association of Utah</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Sexsmith</last_name>
      <phone>801-213-2522</phone>
      <email>corinne.sexsmith@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marie Gibson</last_name>
      <phone>801-213-2845</phone>
      <email>marie.gibson@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lori Gawron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>emergency contraception</keyword>
  <keyword>contraceptive implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be available to share with other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT04678817/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT04678817/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

